Retatrutide's 80-week trial shows weight loss and knee pain relief

Researchers randomly assigned 2,339 adults with obesity but not diabetes to receive a once-weekly injection of retatrutide at 4 mg, 9 mg, or 12 mg, or a placebo, for 80 weeks ¹. At the end, mean body weight fell 17.6% on 4 mg, 23.7% on 9 mg, and 25.0% on 12 mg, compared with 3.9% on placebo ¹. The differences for the two higher doses were 19.8 and 21.0 percentage points ¹. In everyday terms, people on the higher doses lost roughly a quarter of their starting weight, while people on placebo lost a small fraction.

The trial used a treatment-regimen estimand, a way of counting results that keeps people in the analysis even if they stop the assigned injections ¹. That approach usually gives a smaller average effect than only measuring people who complete the full course. The result is still large and consistent with earlier studies.

This finding is not a surprise. The retatrutide research summary already covers earlier phase 2 and phase 3 results, including a 48-week phase 2 obesity trial where 12 mg produced a mean 24.2% weight loss ³. A systematic review of phase 3 trials estimated mean weight loss around 28.7% ⁴. The new 80-week result sits between those numbers. It confirms the weight effect with a longer follow-up and a larger, separate group.

The trial had three primary outcomes: body weight, knee pain score, and apnea-hypopnea index ¹. Within the obesity trial, 574 participants also had knee osteoarthritis, a condition where joint cartilage breaks down and causes pain ¹. The study used the WOMAC pain score, a standard questionnaire that runs from 1 to 10, with higher numbers meaning worse pain ¹. On the trial's primary method, pain scores dropped by 3.2, 3.5, and 3.6 points in the 4 mg, 9 mg, and 12 mg groups, compared with 1.9 points on placebo ¹. The differences for the 9 mg and 12 mg doses were 1.6 and 1.8 points, and both were statistically significant ¹. In plain language, knee pain improved more in people who received retatrutide than in people who received a placebo.

The same trial also tracked sleep apnea, a condition where breathing pauses during sleep, in 243 participants ¹. The apnea-hypopnea index, a count of breathing pauses per hour, was listed as a primary outcome ¹. The available abstract did not include those sleep numbers, so this report cannot compare them.

A second phase 3 trial, called TRIUMPH-2, randomly assigned 1,152 adults with obesity and type 2 diabetes to the same three doses or placebo for 80 weeks ². It enrolled people with a body mass index of at least 27 and an HbA1c between 6.5% and 10.5%, on stable diabetes treatment before screening ². All participants had a history of at least one self-reported unsuccessful dietary effort to lose weight ². The primary endpoint was the percentage change in body weight at week 80 for the 9 mg and 12 mg doses compared with placebo ². The abstract provided does not include the weight result.

The design matters because it tests retatrutide in the common situation where obesity and type 2 diabetes overlap. An earlier 40-week phase 3 trial in type 2 diabetes reported weight loss between 11.5% and 15.3% ⁵. The new 80-week diabetes trial is longer, but until its weight numbers are published, there is no new comparison to make.

The table below compares the new 80-week evidence with the earlier trial information used on the retatrutide page.

The pattern across the obesity trials is consistent. Higher doses produced more weight loss, and the 12 mg dose remained in the low-to-mid twenties percent range. The diabetes trial uses the same doses and duration as the obesity trial, which will make future comparisons cleaner.

Trial data already list nausea, vomiting, and diarrhea among the most common side effects of retatrutide, with dose-dependent frequency ⁷. In the phase 3 diabetes trial, slower dose increases cut treatment discontinuation to 2 to 5 percent ⁵. But not every report comes from a monitored trial.

A case report describes a woman in her mid-20s who received four weekly injections from a wellness setting, using an unverified product said to contain retatrutide ⁶. She developed five days of persistent nausea, repeated vomiting, loose stools, and reduced food intake ⁶. The symptoms did not fully respond to several anti-nausea medicines at first, then improved after admission and resolved within a week ⁶. A standard causality tool called the Naranjo score rated the link as probable ⁶. The woman did not consider the injections to be medication ⁶.

This case is a reminder that products sold outside clinical trials may be mislabeled or may carry different risks than the tested medicine. Earlier work in Australia found composition and labeling failures in products sold as retatrutide online ⁸.

The 80-week obesity trial reports knee pain results but does not provide sleep apnea numbers in the abstract reviewed ¹. The diabetes trial's weight result is not yet available in the provided abstract ². Longer follow-up will also be needed to see whether the knee and sleep benefits hold after treatment stops, and whether the weight returns. The case report cannot tell us how common severe nausea is, only that it can happen with unverified products. Until the full trial reports arrive, the longer-term picture for knee pain and sleep apnea remains incomplete.